Skip to main content
Psychedex

1Provenance card

the boundary, as counts

Sources

3016 with DOI

3 strong · 19 moderate · 8 weak

Compilations

12026-05-10T23:00:24.683Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

34last ruled 2026-10-02

0 awaiting a ruling

Issued documents

72026-10-19T20:30:13.373Z

notice · info card · emergency

Searches

173 with no results

queries and counts on the build

Claims checked

5739 supported

39 supported · 18 not

Correspondence

0received

consent field ships in Phase 4

Edges

218

derivations recorded for this entity

Complete over 30 sources, 1 compilation, and 34 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/5-meo-dibf/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued emergency
  2. 2026-10-19issueIssued info_card
  3. 2026-10-02issueIssued info_card
  4. 2026-10-02issueIssued notice
  5. 2026-10-02srcNeurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors
  6. 2026-10-02srcNeurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats.
  7. 2026-10-02srcIn vivo and in vitro toxicokinetics including metabolism, isozyme mapping, and MAO inhibition of three APBT psychedelics
  8. 2026-10-02srcReceptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice
  9. 2026-10-02srcN-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues
  10. 2026-10-02srcStructural pharmacology and therapeutic potential of 5-methoxytryptamines.
  11. 2026-10-02srcReports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A Review
  12. 2026-10-02srcEfficacy of cyproheptadine in the management of serotonin toxicity following deliberate self-poisoning - A systematic review
  13. 2026-10-02srcSerotonin syndrome (toxicity): pathophysiology, incidence, clinical assessment and management
  14. 2026-10-02srcPharmacological profile of novel psychoactive benzofurans
  15. 2026-10-02srcAbuse liability profile of three substituted tryptamines
  16. 2026-10-02srcPharmacologic Activity of Substituted Tryptamines at 5-HT2A, 5-HT2C, 5-HT1A Receptors and SERT
  17. 2026-10-02srcIndolealkylamines: biotransformations and potential drug-drug interactions
  18. 2026-10-02srcPsychedelics and the human receptorome
  19. 2026-10-02srcPeakAL: Protons I Have Known and Loved, Too — Another Fifty Shades of Grey-Market Spectra
  20. 2026-10-02srcSerotonin syndrome: understanding pathophysiological bases and managing a growing clinical challenge
  21. 2026-10-02srcSchedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.
  22. 2026-10-02srcMonoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.
  23. 2026-10-02srcHallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats.
  24. 2026-10-02srcEffects of 5-Methoxy-N,N-di(ISO)propyltryptamine hydrochloride (Foxy) on cognitive development in rats
  25. 2026-10-02src5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter
  26. 2026-10-02srcIn vitro screening of psychoactive drugs by [(35)S]GTPgammaS binding in rat brain membranes.
  27. 2026-10-02srcFoxy methoxy: a new drug of abuse.
  28. 2026-10-02srcNeuropsychotoxicity of abused drugs: molecular and neural mechanisms induced by methamphetamine, MDMA, and 5-MeO-DiPT.
  29. 2026-10-02src5-MeO-DiBF (HandWiki)
  30. 2026-10-02src5-MeO-DiBF Experience Vault Index (Erowid)
  31. 2026-10-02srcDEA Final Rule: Placement of AMT and 5-MeO-DiPT into Schedule I (2004)
  32. 2026-10-02src5-MeO-DiBF Experience Report: Disappointed (Erowid)
  33. 2026-10-02srcEMCDDA-Europol 2016 Annual Report on New Psychoactive Substances
  34. 2026-10-02src5-MeO-DiBF (PsychonautWiki)
  35. 2026-10-02publicationPublication — publishagent-psx
  36. 2026-10-02revisionr1.a1
  37. 2026-10-02rulingRuling — psx:substance/5-meo-dibf/proposal/article_section_proposals/19f9de54-7a82-4aa0-af27-fa74f0d1e583founder
  38. 2026-10-02rulingRuling — psx:substance/5-meo-dibf/proposal/article_section_proposals/328a71ed-4e8b-45a6-9d59-e076ee08b6fdfounder
  39. 2026-09-04issueIssued emergency
  40. 2026-09-04issueIssued info_card
  41. 2026-09-04issueIssued notice
  42. 2026-06-04proposal28 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  43. 2026-06-04publicationPublication — backfill
  44. 2026-05-10revisionRevision 1
  45. 2026-05-10absenceSearched ClinicalTrials.gov for "5-MeO-DiBF benzofuran tryptamine psychedelic" — no results
  46. 2026-05-10absenceSearched PubMed for "5-methoxy-N,N-diisopropyltryptamine benzofuran analog pharmacology" — no results
  47. 2026-05-10absenceSearched ClinicalTrials.gov for "5-MeO-DiBF benzofuran tryptamine psychedelic" — no results
  48. 2026-05-10genGeneration — pipeline-v5 · with 4 morepipeline-v5
  49. 2026-05-10rungeneration run

The same entries, as forms: six forms.